MindMeds Systematic Biotech Approach With New FDA Therapy Designation, 12-Week Clinical Data, Plus Expected $175M Proceeds
MindMeds Systematic Biotech Approach With New FDA Therapy Designation, 12-Week Clinical Data, Plus Expected $175M Proceeds
MindMeds的系統生物技術方法，包括新的FDA療法名稱，12周的臨床數據，以及預期的1.75億美元收益
Shortly following the news on FDA's "breakthrough therapy" designation and the 12-week clinical durability data on its LSD therapy for generalized anxiety, psychedelics biotech MindMed (NASDAQ:MNMD) announced the pricing of an underwritten offering of 16,666,667 common shares, no par value per share, at an offering price of $6.00 each.
在美國食品藥品管理局獲得 “突破性療法” 稱號的消息以及其針對廣泛性焦慮的迷幻藥療法的12周臨床耐久性數據發佈後不久，迷幻藥生物技術公司MindMed（納斯達克股票代碼：MNMD）宣佈承銷發行16,666,667股普通股的定價，每股無面值，每股6.00美元。
The company has also entered into share purchase agreements for a concurrent private placement of 12,500,000 common shares, at an individual price of $6.00. All these shares are being sold by MindMed to new investors Deep Track Capital and Commodore Capital.
該公司還簽訂了股票購買協議，以同時私募12,500,000股普通股，個人價格爲6.00美元。所有這些股票都由MindMed出售給新投資者Deep Track Capital和Commodore Capital。
Meanwhile, the underwritten offering reportedly includes participation from new investors Ally Bridge...
同時，據報道，承銷發行包...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。